

# Tomoki Todo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7431454/publications.pdf>

Version: 2024-02-01

67  
papers

3,402  
citations

172457

29  
h-index

144013

57  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3791  
citing authors

#	ARTICLE	IF	CITATIONS
1	PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma-initiating cell properties via DNA methyltransferase 3A. <i>Molecular Oncology</i> , 2022, 16, 269-288.	4.6	5
2	SMURF2 phosphorylation at Thr249 modifies glioma stemness and tumorigenicity by regulating TGF- $\beta$ 2 receptor stability. <i>Communications Biology</i> , 2022, 5, 22.	4.4	8
3	Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 225-235.	4.4	1
4	Therapeutic advantage of targeting lysosomal membrane integrity supported by lysophagy in malignant glioma. <i>Cancer Science</i> , 2022, 113, 2716-2726.	3.9	6
5	Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies. <i>Molecular Therapy</i> , 2021, 29, 762-774.	8.2	22
6	Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms. <i>British Journal of Haematology</i> , 2021, 192, 343-353.	2.5	15
7	Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer. <i>Oncotarget</i> , 2021, 12, 344-354.	1.8	7
8	CDK8 maintains stemness and tumorigenicity of glioma stem cells by regulating the c-MYC pathway. <i>Oncogene</i> , 2021, 40, 2803-2815.	5.9	33
9	Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer. <i>Oncology Letters</i> , 2021, 21, 490.	1.8	6
10	Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors. <i>Cancer Science</i> , 2021, 112, 3293-3301.	3.9	13
11	Oncolytic herpes virus G47 $\Delta$ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 129-142.	4.4	37
12	Oncolytic herpes virus G47 $\Delta$ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 388-398.	4.4	14
13	Efficacy and safety of a third-generation oncolytic herpes virus G47 $\Delta$ in models of human esophageal carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 402-411.	4.4	17
14	Efficacy of a Third-Generation Oncolytic Herpes Virus G47 $\Delta$ in Advanced Stage Models of Human Gastric Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 205-215.	4.4	48
15	Neoadjuvant Use of Oncolytic Herpes Virus G47 $\Delta$ Enhances the Antitumor Efficacy of Radiofrequency Ablation. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 535-545.	4.4	23
16	Tyrosine kinase Eph receptor A6 sensitizes glioma-initiating cells towards bone morphogenetic protein-induced apoptosis. <i>Cancer Science</i> , 2019, 110, 3486-3496.	3.9	13
17	Foxr2 promotes formation of CNS-embryonal tumors in a Trp53-deficient background. <i>Neuro-Oncology</i> , 2019, 21, 993-1004.	1.2	13
18	Aberrant Active cis-Regulatory Elements Associated with Downregulation of RET Finger Protein Overcome Chemoresistance in Glioblastoma. <i>Cell Reports</i> , 2019, 26, 2274-2281.e5.	6.4	8

#	ARTICLE	IF	CITATIONS
19	ATIM-14. RESULTS OF PHASE II CLINICAL TRIAL OF ONCOLYTIC HERPES VIRUS G47 <sup>Δ</sup> IN PATIENTS WITH GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi4-vi4.	1.2	37
20	Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 201-209.	1.3	55
21	Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models. <i>Oncotarget</i> , 2019, 10, 7132-7141.	1.8	13
22	Enhancement of the efficacy of radiofrequency ablation by neoadjuvant oncolytic virus therapy via antitumor immunity and the booster effect of immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 253-253.	1.6	1
23	Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies. <i>Blood</i> , 2019, 134, 3242-3242.	1.4	0
24	Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. <i>Cancer Science</i> , 2018, 109, 600-610.	3.9	24
25	Identification of a novel fusion gene <i>HMGA2-EGFR</i> in glioblastoma. <i>International Journal of Cancer</i> , 2018, 142, 1627-1639.	5.1	12
26	<i>SIRT</i> -mediated inactivation of p73 is required for glioblastoma tumorigenicity. <i>EMBO Reports</i> , 2018, 19, .	4.5	35
27	Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas. <i>Cancer Science</i> , 2018, 109, 2497-2508.	3.9	16
28	The role of the SWI/SNF chromatin remodeling complex in maintaining the stemness of glioma initiating cells. <i>Scientific Reports</i> , 2017, 7, 889.	3.3	32
29	Current status of clinical trials assessing oncolytic virus therapy for urological cancers. <i>International Journal of Urology</i> , 2017, 24, 342-351.	1.0	38
30	Significance of perivascular tumour cells defined by CD109 expression in progression of glioma. <i>Journal of Pathology</i> , 2017, 243, 468-480.	4.5	36
31	MiR-199a Inhibits Secondary Envelopment of Herpes Simplex Virus-1 Through the Downregulation of Cdc42-specific GTPase Activating Protein Localized in Golgi Apparatus. <i>Scientific Reports</i> , 2017, 7, 6650.	3.3	6
32	Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug. <i>Oncotarget</i> , 2017, 8, 111728-111741.	1.8	29
33	Oncolytic Virus Therapy for Malignant Glioma using G47 <sup>Δ</sup> . <i>Japanese Journal of Neurosurgery</i> , 2016, 25, 973-978.	0.0	0
34	Oncolytic virus therapy: A new era of cancer treatment at dawn. <i>Cancer Science</i> , 2016, 107, 1373-1379.	3.9	527
35	Therapeutic Strategy for Targeting Aggressive Malignant Gliomas by Disrupting Their Energy Balance. <i>Journal of Biological Chemistry</i> , 2016, 291, 21496-21509.	3.4	31
36	Identification of RNA-Binding Protein LARP4B as a Tumor Suppressor in Glioma. <i>Cancer Research</i> , 2016, 76, 2254-2264.	0.9	41

#	ARTICLE	IF	CITATIONS
37	MICRO RNA BASED STRATEGY FOR ENHANCING THE EFFECT OF ONCOLYTIC HSV-1 VIRUS THERAPY. <i>Neuro-Oncology</i> , 2014, 16, iii37-iii37.	1.2	0
38	A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy. <i>Radiation Oncology</i> , 2014, 9, 237.	2.7	25
39	PCDH10 is required for the tumorigenicity of glioblastoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 444, 13-18.	2.1	12
40	An armed oncolytic herpes simplex virus expressing thrombospondinâ€1 has an enhanced <i>in vivo</i> antitumor effect against human gastric cancer. <i>International Journal of Cancer</i> , 2013, 132, 485-494.	5.1	39
41	Active Immunotherapy Oncolytic Virus Therapy Using HSV-1. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 178-186.	1.6	27
42	Extended field stereotactic radiosurgery for recurrent glioblastoma. <i>Cancer</i> , 2012, 118, 4193-4200.	4.1	45
43	Glioma-initiating Cells Retain Their Tumorigenicity through Integration of the Sox Axis and Oct4 Protein. <i>Journal of Biological Chemistry</i> , 2011, 286, 41434-41441.	3.4	129
44	CLINICAL DEVELOPMENT OF A THIRD-GENERATION ONCOLYTIC HSV-1 (G47 <sup>Δ</sup> ) FOR MALIGNANT GLIOMA. <i>Gene Therapy and Regulation</i> , 2010, 05, 101-111.	0.3	8
45	Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. <i>Neuro-Oncology</i> , 2009, 11, 446-451.	1.2	49
46	Autocrine TGF- $\beta$ 2 Signaling Maintains Tumorigenicity of Glioma-Initiating Cells through Sry-Related HMG-Box Factors. <i>Cell Stem Cell</i> , 2009, 5, 504-514.	11.1	503
47	â€Armedâ€ oncolytic herpes simplex viruses for brain tumor therapy. <i>Cell Adhesion and Migration</i> , 2008, 2, 208-213.	2.7	23
48	Oncolytic virus therapy using genetically engineered herpes simplex viruses. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 2060.	3.0	66
49	Preoperative Mapping of Language-related Functions using Functional MRI and Magnetoencephalography (&lt;SPECIAL ISSUE&gt; Functional Neurophysiological Monitoring for) <i>Tj ETQq1 1 0.784314 rgBT (Overlock</i>		
50	Clinical Practice and Perspectives in Neurosurgery using Multi-modality Functional Imaging and Monitoring. <i>Japanese Journal of Neurosurgery</i> , 2007, 16, 206-214.	0.0	0
51	Triple Combination of Oncolytic Herpes Simplex Virus-1 Vectors Armed with Interleukin-12, Interleukin-18, or Soluble B7-1 Results in Enhanced Antitumor Efficacy. <i>Clinical Cancer Research</i> , 2006, 12, 643-652.	7.0	103
52	Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 6791-6799.	7.0	72
53	Oncolytic HSV Armed with Platelet Factor 4, an Antiangiogenic Agent, Shows Enhanced Efficacy. <i>Molecular Therapy</i> , 2006, 14, 789-797.	8.2	77
54	Brain Tumor Therapy using Oncolytic Herpes Simplex Virus Vectors. <i>Japanese Journal of Neurosurgery</i> , 2006, 15, 97-104.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Triple Gene-Deleted Oncolytic Herpes Simplex Virus Vector Double-Armed with Interleukin 18 and Soluble B7-1 Constructed by Bacterial Artificial Chromosome-Mediated System. <i>Cancer Research</i> , 2005, 65, 10663-10668.	0.9	104
56	Oncolytic Herpes Simplex Virus Vector G47 $\Delta$ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 7886-7890.	7.0	57
57	Development of Oncolytic Replication-Competent Herpes Simplex Virus Vectors. , 2005, , 199-210.		2
58	Oncolytic Virus Therapy Using Genetically Engineered Herpes Simplex Viruses. <i>Human Cell</i> , 2002, 15, 151-159.	2.7	18
59	Ionizing Radiation Does Not Alter the Antitumor Activity of Herpes Simplex Virus Vector G207 in Subcutaneous Tumor Models of Human and Murine Prostate Cancer. <i>Neoplasia</i> , 2001, 3, 451-456.	5.3	48
60	Therapeutic Efficacy of G207, a Conditionally Replicating Herpes Simplex Virus Type 1 Mutant, for Gallbladder Carcinoma in Immunocompetent Hamsters. <i>Molecular Therapy</i> , 2001, 3, 431-437.	8.2	44
61	Preclinical Safety Evaluation of G207, a Replication-Competent Herpes Simplex Virus Type 1, Inoculated Intraprostatically in Mice and Nonhuman Primates. <i>Human Gene Therapy</i> , 2001, 12, 999-1010.	2.7	67
62	Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. <i>Cancer Gene Therapy</i> , 2000, 7, 939-946.	4.6	51
63	Viral Shedding and Biodistribution of G207, a Multimutated, Conditionally Replicating Herpes Simplex Virus Type 1, after Intracerebral Inoculation in Aotus. <i>Molecular Therapy</i> , 2000, 2, 588-595.	8.2	90
64	Corticosteroid Administration Does Not Affect Viral Oncolytic Activity, but Inhibits Antitumor Immunity in Replication-Competent Herpes Simplex Virus Tumor Therapy. <i>Human Gene Therapy</i> , 1999, 10, 2869-2878.	2.7	50
65	Replication-Competent Herpes Simplex Virus Vector G207 and Cisplatin Combination Therapy for Head and Neck Squamous Cell Carcinoma. <i>Neoplasia</i> , 1999, 1, 162-169.	5.3	104
66	Systemic Antitumor Immunity in Experimental Brain Tumor Therapy Using a Multimutated, Replication-Competent Herpes Simplex Virus. <i>Human Gene Therapy</i> , 1999, 10, 2741-2755.	2.7	193
67	Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates. <i>Journal of Virology</i> , 1999, 73, 6319-6326.	3.4	171